Home › Funds › Opaleye Management Inc. › TGTX

Opaleye Management Inc. position in TGTX

TG THERAPEUTICS · Health Care

Opaleye Management Inc. reported holding 535,000 shares of TGTX (TG THERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$29.4M, representing 2.66% of its reported portfolio and ranking #10 among its reported holdings. Opaleye Management Inc. has disclosed TGTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)535.00K sh
Reported value held$29.39M
Portfolio Weight2.66%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Opaleye Management Inc.'s TGTX position evolved

Opaleye Management Inc. first disclosed a stake in TGTX in Q3 2023 at 1,890,000 shares (US$15.8M). The position peaked in Q4 2024 at 2,260,000 shares, worth US$68.0M. Across 12 filings, Opaleye Management Inc. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 535,000 shares valued at US$29.4M. Notable position changes include a 76% trim in Q1 2025 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.89M $15.80M New
Q4 2023 2.21M $37.83M Add
Q1 2024 2.28M $34.68M Add
Q2 2024 2.28M $40.56M Hold
Q3 2024 2.28M $53.33M Hold
Q4 2024 2.26M $68.03M Reduce
Q1 2025 535.00K $21.10M Reduce
Q2 2025 535.00K $19.25M Hold
Q3 2025 535.00K $19.33M Hold
Q4 2025 535.00K $15.95M Hold
Q1 2026 535.00K $17.77M Hold
Q2 2026 535.00K $29.39M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TGTX and 13F data

TGTX (TG THERAPEUTICS) is a Health Care company. 52 other funds we track also report a position in TGTX — the largest reported positions include Soleus Capital Management, L.P. (US$160.9M), CONGRESS ASSET MANAGEMENT CO (US$145.4M), Penn Capital Management Company, LLC (US$29.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TGTX

All TGTX fund holders →

FAQ

How long has Opaleye Management Inc. held TGTX?

Opaleye Management Inc. has disclosed TGTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Opaleye Management Inc.'s current position in TGTX?

As of Q2 2026, Opaleye Management Inc. holds 535.00K shares of TGTX (TG THERAPEUTICS), valued at $29.39M, representing 2.66% of its reported portfolio and ranking #10.

Has Opaleye Management Inc. been buying or selling TGTX?

In the latest 13F filing (Q2 2026), Opaleye Management Inc. held unchanged its position in TGTX. The position peaked in Q4 2024 at 2.26M shares.

Which other funds hold TGTX?

Other major institutional holders of TGTX include Soleus Capital Management, L.P., CONGRESS ASSET MANAGEMENT CO, Penn Capital Management Company, LLC, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.